MARKET

INO

INO

Inovio Pharmaceu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.790
-0.030
-1.65%
After Hours: 1.790 0 0.00% 16:21 06/29 EDT
OPEN
1.790
PREV CLOSE
1.820
HIGH
1.835
LOW
1.730
VOLUME
6.15M
TURNOVER
0
52 WEEK HIGH
9.96
52 WEEK LOW
1.380
MARKET CAP
409.98M
P/E (TTM)
-1.1613
1D
5D
1M
3M
1Y
5Y
INOVIO appoints Dr. Michael Sumner as CMO
INOVIO (NASDAQ:INO) has announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer. He will serve on the company's executive leadership team and will report to
Seekingalpha · 2d ago
'There are almost 800 cases of monkeypox across the UK' -Evening Standard Report
https://www.standard.co.uk/news/health/monkeypox-cases-london-uk-stats-daily-figures-england-b1007436.html?utm_medium=Social&utm_source=Twitter#Echobox=1655814164-2
Benzinga · 06/21 12:27
Inovio Pharma, Bionano Genomics among health care stocks to join Russell Microcap Index; Tonix Pharma, iBio to leave
FTSE Russell has released a preliminary lists of companies set to join or leave the Russell Microcap Index as part of its 2022 annual reconstitution. Notable health care additions include: Inovio Pharma
Seekingalpha · 06/06 15:59
Is Inovio Pharmaceuticals (NASDAQ:INO) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Simply Wall St. · 05/28 13:49
10 Small-Cap Stocks to Sell Now Before Recession Begins
In this article, we discuss 10 small-cap stocks to sell now before recession begins. If you want to read about some more small-cap stocks to sell now before recession begins, go directly to 5 Small-Cap Stocks to Sell Now Before Recession Begins. The United...
Insider Monkey · 05/28 13:02
Inovio announces positive survival results from trial testing glioblastoma treatment
Inovio (NASDAQ:INO +2.9%) said on Friday its therapy, INO-5401 + INO-9012, was tolerable and immunogenic when administered with Libtayo, with radiation and chemotherapy, to newly diagnosed glioblastoma patients, in an early-to-mid stage trial.
Seekingalpha · 05/27 13:51
BRIEF-Inovio Announces Survival Results For Ino-5401 + Ino-9012 In Combination With Libtayo (Cemiplimab) In Patients With Newly Diagnosed GBM At Asco Annual Meeting 2022
reuters.com · 05/27 12:14
INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022
INOVIO's DNA medicines immunotherapy in combination with Libtayo® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients INO-5401 + INO-9012 +
Benzinga · 05/27 12:02
More
No Data
Learn about the latest financial forecast of INO. Analyze the recent business situations of Inovio Pharmaceu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
12.50%Buy
87.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average INO stock price target is 5.00 with a high estimate of 11.00 and a low estimate of 1.000.
High11.00
Average5.00
Low1.000
Current 1.790
EPS
Actual
Estimate
-0.40-0.30-0.20-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 319
Institutional Holdings: 94.52M
% Owned: 41.27%
Shares Outstanding: 229.04M
TypeInstitutionsShares
Increased
52
15.05M
New
25
3.60M
Decreased
54
5.54M
Sold Out
31
7.07M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.63%
Key Executives
President/Chief Executive Officer/Director
Jacqueline Shea
Non-Executive Vice Chairman/Independent Director
Jay Shepard
Chief Financial Officer
Peter Kies
Chief Human Resource Officer
Asli Gevgilili
Chief Scientific Officer
Laurent Humeau
General Counsel
Robert Crotty
Other
Gene Kim
Other
Michael Sumner
Other
Mark Twyman
Director
David Weiner
Independent Director
Roger Dansey
Independent Director
Ann Miller
Independent Director
Wendy Yarno
Independent Director
Lota Zoth
No Data
No Data
About INO
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Webull offers kinds of Inovio Pharmaceuticals Inc stock information, including NASDAQ:INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.